Genentech Inc.'s treatment for cystic fibrosis, Pulmozyme (dornasealfa) is now being marketed in Ireland, the South San Francisco, Calif.,company announced. The drug will be marketed in Ireland under acollaborative agreement with F. Hoffman-La Roche, Ltd. The drug hasalready been approved for sale in the U.S., Canada, Austria, NewZealand, Argentina, and the U.K. Genentech (NYSE:GNE) says itexpects approval in other European countries soon.

(c) 1997 American Health Consultants. All rights reserved.